La Jolla Pharmaceutical (LJPC) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a research note released on Saturday.

Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group lowered their target price on shares of La Jolla Pharmaceutical from $23.00 to $22.00 and set an underperform rating on the stock in a research note on Thursday, August 9th. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, September 27th. HC Wainwright restated a buy rating and set a $53.00 target price on shares of La Jolla Pharmaceutical in a research note on Friday, September 7th. JPMorgan Chase & Co. lowered their target price on shares of La Jolla Pharmaceutical from $24.00 to $21.00 and set an underweight rating on the stock in a research note on Friday, August 10th. Finally, BidaskClub cut shares of La Jolla Pharmaceutical from a buy rating to a hold rating in a research note on Thursday, August 16th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. La Jolla Pharmaceutical has a consensus rating of Hold and an average price target of $49.29.

LJPC opened at $15.97 on Friday. The stock has a market cap of $443.61 million, a price-to-earnings ratio of -2.95 and a beta of 1.39. La Jolla Pharmaceutical has a 52-week low of $14.65 and a 52-week high of $41.36.



La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its earnings results on Wednesday, October 24th. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.01) by $0.08. The company had revenue of $3.47 million for the quarter, compared to the consensus estimate of $3.38 million. On average, equities research analysts forecast that La Jolla Pharmaceutical will post -8.1 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of LJPC. Schwab Charles Investment Management Inc. lifted its stake in shares of La Jolla Pharmaceutical by 14.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,430 shares of the biopharmaceutical company’s stock worth $2,574,000 after purchasing an additional 11,132 shares during the period. UBS Group AG lifted its stake in shares of La Jolla Pharmaceutical by 529.3% in the 1st quarter. UBS Group AG now owns 97,622 shares of the biopharmaceutical company’s stock worth $2,907,000 after purchasing an additional 82,109 shares during the period. WINTON GROUP Ltd bought a new position in shares of La Jolla Pharmaceutical in the 1st quarter worth approximately $276,000. Hollencrest Capital Management bought a new position in shares of La Jolla Pharmaceutical in the 2nd quarter worth approximately $321,000. Finally, Fox Run Management L.L.C. bought a new position in shares of La Jolla Pharmaceutical in the 2nd quarter worth approximately $284,000.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Featured Story: What are the components of an earnings report?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply